Restoration of normal blood coagulation with chitosan in the simulation of hypocoagulation with aspirin

Мұқаба

Дәйексөз келтіру

Толық мәтін

Аннотация

The study of changes in blood clotting parameters under in vitro conditions with different incubation durations (5 min and 30 min) of chitosan with normal and with hypocoagulation plasma of rats was carried out. The addition of chitosan to the plasma of normal animals led to an increase in its procoagulant activity regardless of the duration of incubation. However, an increase in the incubation time to 30 min contributed to a more significant decrease in the fibrin-depolymerization activity of the blood. Incubation of chitosan with hypocoagulation plasma obtained after administration of acetylsalicylic acid (aspirin) to animals (once, orally at a dose of 2 mg / kg) for both 5 minutes and 30 minutes led to pronounced activation of blood clotting. Under these conditions, the lengthening of the incubation time caused more pronounced effects of this drug: a significant increase in the concentration of fibrinogen, ADP-dependent platelet aggregation, the degree of fibrin polymerization and a decrease in non-enzymatic fibrinolysis. At the same time, most of the studied hemostasis parameters approached values corresponding to the normal level. The results obtained in this work indicate the high effectiveness of chitosan as a means of restoring normal blood clotting, blocking the phenomena of bleeding in hypocoagulation conditions.

Толық мәтін

Рұқсат жабық

Авторлар туралы

M. Grigorjeva

Lomonosov Moscow State University

Хат алмасуға жауапты Автор.
Email: mgrigorjeva@mail.ru
Ресей, Moscow

T. Obergan

Lomonosov Moscow State University

Email: mgrigorjeva@mail.ru
Ресей, Moscow

L. Lyapina

Lomonosov Moscow State University

Email: mgrigorjeva@mail.ru
Ресей, Moscow

T. Shubina

Lomonosov Moscow State University

Email: mgrigorjeva@mail.ru
Ресей, Moscow

Әдебиет тізімі

  1. Забивалова Н.М., Юдин А.Б. Основные механизмы гемостатического действия хитозана // Прикладные вопросы военной медицины / Мат. Всерос. науч.-практ. конф. (Санкт-Петербург, 22–23 сентября 2021 г.). СПб.: ГНИИИВМ, 2021. С. 226–232.
  2. Киселевский Д.Б., Шагдарова Б.Ц., Варламов В.П. и др. Действие низкомолекулярного хитозана на клетки эпидермиса из листьев гороха // Вестн. Моск. ун-та. Сер. 16. Биология. 2021. Т. 76 (1). С. 18–23.
  3. Кузник Б.И. Клеточные и молекулярные механизмы регуляции системы гемостаза в норме и патологии. Чита: Экспресс-издательство, 2010. 832 с.
  4. Ляпина Л.А., Григорьева М.Е., Оберган Т.Ю., Шубина Т.А. Исследование гемостатических свойств препарата на основе хитозана // Биофарм. журн. 2022а. Т. 14 (1). С. 3–7.
  5. Ляпина Л.А., Оберган Т.Ю., Григорьева М.Е., Шубина Т.А. Влияние хитозана на свертывание крови гепаринизированных крыс // Изв. РАН. Сер. биол. 2022б. № 6. С. 636–641.
  6. Ляпина Л.А., Григорьева М.Е., Шубина Т.А., Оберган Т.Ю. Основы физиологии и биохимии свертывания крови. М.: МГУ, 2023. 159 с.
  7. Шубина Т.А., Оберган Т.Ю., Ляпина Л.А., Григорьева М.Е. Влияние полисахарида хитозана на плазменный гемостаз: исследование in vitro // Тромбоз, гемостаз и реология. 2022. № 4. С. 30–34.
  8. Aktop S., Emekli-Alturfan E., Ozer C. et al. Effects of ankaferd blood stopper and celox on the tissue factor activities of warfarin-treated rats // Clin. Appl. Thromb. Hemost. 2014. V. 20 (1). P. 16–21.
  9. Capodanno D., Angiolillo D. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus // Circulation. 2016. V. 134 (20). P. 1579–1594.
  10. Cassano R., Di Gioia M.L., Mellace S. et al. Hemostatic gauze based on chitosan and hydroquinone: preparation, characterization and blood coagulation evaluation // J. Mater. Sci. Mater. Med. 2017. V. 28 (12). P. 190–199.
  11. Gheorghiţă D., Moldovan H., Robu A. et al. Chitosan-based biomaterials for hemostatic applications: a rewiew of recent advances // Int. J. Mol. Sci. 2023. V. 24 (13). P. 10540.
  12. Chou T.-C., Fu E., Wu C.-J., Yen J.-H. Chitosan enhances platelet adhesion and aggregation // Biochem. Biophys. Res. Commun. 2003. V. 302 (3). P. 480–483.
  13. Lee V.K., Lee T., Ghosh A. et al. An architecturally rational hemostat for rapid stopping of massive bleeding on anticoagulation therapy // PNAS USA. 2024. V. 121 (5). P. e2316170121.
  14. Lichtenberger L.M., Vijayan K.V. Are platelets the primary target of aspirin′s remarkable anticancer activity? // Cancer Res. 2019. V. 79 (15). Р. 3820–3823.
  15. Malik A., Rehman F.U., Shah K.U. et al. Hemostatic strategies for uncontrolled bleeding: a comprehensive update // J. Biomed. Mater. Res. B Appl. Biomater. 2021. V. 109. P. 1465–1477.
  16. Murphy E., Curneen J.M.G., McEvoy J.W. Aspirin in the modern era of cardiovascular disease prevention // Methodist Debakey Cardiovasc. J. 2021. V. 17 (4). P. 36–47.
  17. Neveleff D.J., Kraiss L.W., Schulman C.S. Implementing methods to improve perioperative hemostasis in the surgical and trauma setting // AORN J. 2010. V. 92 (5). P. S1–S15.
  18. Periayah M.H., Halim A.S., Yaacob N.S. et al. Glycoprotein IIb/IIIa and P2Y12 induction by oligochitosan accelerates platelet aggregation // Biomed. Res. Int. 2014. V. 2014. P. 653149.
  19. Pereira B.M., Bortoto J.B., Fraga G.P. Topical hemostatic agents in surgery: review and prospects // Rev. Col. Bras. Cir. 2018. V. 45 (5). P. e1900.
  20. Rodriguez-Merchan E.C. Local fibrin glue and chitosan-based dressings in haemophilia surgery // Blood Coagul. Fibrinol. 2012. V. 23 (6). Р. 473–476.
  21. Sheppard O.O., Foje N.A. Topical coagulant agents // Surg. Clin. North Am. 2022. V. 102 (1). P. 65–83.
  22. Undas A., Brummel-Ziedins K., Mann K. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions // Blood. 2007. V. 107. P. 2285–2292.
  23. Wang W., Xue C., Mao X. Chitosan: structural modification, biological activity and application // Int. J. Biol. Macromol. 2020. V. 164. P. 4532–4546.
  24. Zhang W., Zhong D., Liu Q. et al. Effect of chitosan and carboxymethyl chitosan on fibrinogen structure and blood coagulation // J. Biomater. Sci. Polym. Ed. 2013. V. 24 (13). P. 1549–1563.
  25. Zheng S.L., Roddick A.J. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis // JAMA. 2019. V. 321 (3). P. 277–287.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Russian Academy of Sciences, 2024